Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 05 December 2017 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Tuesday finalized guidance on the use of serological tests to reduce the risk of transmission of T. cruzi, a parasite that causes Chagas disease, in blood and blood components.
This guidance supersedes 2010 guidance and finalizes a draft from 2016 that amended the 2010 guidance by expanding its scope to include the collection of blood and blood components for use in manufacturing a product, including donations intended as a component of, or used to manufacture, a medical device; removing the recommendation to ask donors about their Chagas disease histories; and providing a recommendation for a reentry algorithm for certain donors deferred on the basis of screening test results or because they answered "yes" to the Chagas screening question.
Chagas disease, caused by the protozoan parasite T. cruzi, is endemic in Mexico and Central and South Americe. Experts estimate that about 300,000 people unknowingly infected with the parasite reside in the US.
FDA said it received two comments on the 2016 draft, and those comments were considered in finalizing the guidance.
The 18-page guidance features recommendations on donor testing, donor deferral, further testing, notification and the reentry algorithm for donors deferred based on screening test results for antibodies of T. cruzi or pre-donation screening questions.
The guidance also notes that it removed the recommendation on asking blood donors about a history of Chagas based on "the low sensitivity and specificity of the donor question, the significant clinical sensitivity of the two currently licensed screening tests (Refs. 13 and 14), the low (0.8%) risk of transfusion-transmitted T. cruzi infection from a seropositive donor (Ref. 11), and the observation that T. cruzi RIPA positive donors are likely not aware of their infection."
FDA instead recommends "that one-time testing alone, without donor questioning for history of Chagas disease, is adequate and appropriate to identify donors at risk for transmission of Chagas disease."
Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components
Tags: Chagas Disease, blood collection, FDA guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.